Intelligent Bio Solutions Inc. provided unaudited preliminary earnings guidance for the second quarter and six months ended December 31, 2023. The Company expects approximate unaudited revenue of $1.56 million for the six months ended December 31, 2023, representing a significant increase of 337% compared to the same period the prior year, and approximate unaudited revenue of $0.76 million for the second fiscal quarter ended December 31, 2023, representing an increase of 114% compared to the same period the prior year.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.32 USD | +0.43% | +0.43% | -42.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.78% | 7.32M | |
-38.56% | 8.39B | |
+0.18% | 3.32B | |
+9.29% | 2.49B | |
-18.21% | 2.06B | |
-24.57% | 1.59B | |
+32.37% | 1.15B | |
-7.64% | 704M | |
+8.42% | 678M | |
-29.59% | 508M |
- Stock Market
- Equities
- INBS Stock
- News Intelligent Bio Solutions Inc.
- Intelligent Bio Solutions Inc. Provides Unaudited Preliminary Earnings Guidance for the Second Quarter and Six Months Ended December 31, 2023